| Date Filed | Type | Description |
| 08/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Investor presentation, Quarterly results |
| 07/25/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/20/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/20/2023 |
8-K
| Quarterly results |
| 07/17/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/17/2023 |
8-K
| Results of Operations and Financial Condition Interactive Data |
| 07/17/2023 |
8-K
| Quarterly results |
| 06/08/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Investor presentation, Quarterly results |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/27/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 04/27/2023 |
8-K
| Quarterly results |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/28/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/27/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/27/2023 |
8-K
| Investor presentation |
| 03/15/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 02/14/2023 |
SC 13G/A
| Sands Capital Ventures, LLC reports a 8.3% stake in Acumen Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/01/2023 |
8-K
| Quarterly results |
| 01/04/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/24/2022 |
8-K
| Quarterly results |
| 10/07/2022 |
SC 13G/A
| BlackRock Inc. reports a 2.8% stake in Acumen Pharmaceuticals, Inc. |
| 09/12/2022 |
8-K
| Investor presentation |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/15/2022 |
8-K
| Quarterly results |
| 08/01/2022 |
8-K
| Quarterly results |
| 07/11/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/01/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 06/21/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
|